McAdam LLC Sells 1,224 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

McAdam LLC cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,568 shares of the biopharmaceutical company’s stock after selling 1,224 shares during the quarter. McAdam LLC’s holdings in Gilead Sciences were worth $775,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Tompkins Financial Corp increased its stake in shares of Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares during the period. OFI Invest Asset Management bought a new stake in Gilead Sciences in the third quarter valued at approximately $26,000. Fortitude Family Office LLC acquired a new stake in Gilead Sciences during the 4th quarter valued at approximately $29,000. Rakuten Securities Inc. bought a new position in Gilead Sciences during the 4th quarter worth approximately $33,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter valued at $40,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $65.94 on Tuesday. The business’s 50 day simple moving average is $71.16 and its two-hundred day simple moving average is $76.17. Gilead Sciences, Inc. has a one year low of $64.63 and a one year high of $87.86. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.98 and a quick ratio of 0.72. The stock has a market capitalization of $82.10 billion, a P/E ratio of 183.17, a price-to-earnings-growth ratio of 1.29 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The firm had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.37 earnings per share. Analysts forecast that Gilead Sciences, Inc. will post 3.82 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.67%. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on GILD shares. Royal Bank of Canada lowered their target price on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a research note on Friday. Oppenheimer reissued an “outperform” rating and issued a $105.00 price objective on shares of Gilead Sciences in a research note on Friday, April 19th. TD Cowen decreased their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday. UBS Group cut their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Finally, Cantor Fitzgerald dropped their target price on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences has an average rating of “Hold” and a consensus target price of $83.60.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.29% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.